EU Project Fear now says Brexit would put UK access to medicine at risk

Following claims by the Remain camp that beaches could become covered in sewage, millions of jobs would be lost, and terrorism threats would increase, the latest warning is that Britain would lose access to cutting edge medecines in the event of Brexit

by the commentator on 8 May 2016 06:06

Pills

Inviting renewed charges of scaremongering, the campaign for Britain to remain inside the European Union is today promoting claims by a group of well-connected drugs companies and life-science representatives that Brexit could put at risk Britain's access to "cutting edge" medicines.

In a letter to the Observer on Sunday, signed by GSK CEO Sir Andrew Witty and 92 other leading life sciences figures, they say:

"We see significant advantages for the life sciences sector in the UK remaining part of the EU. This would enable the sector to continue to operate within an established and harmonised regulatory approval system, ensuring that UK patients benefit from medicines more quickly, and that medicines researched and manufactured in the UK are available across the EU sooner."

The authors add:

"Leaving the EU would bring added complexity and uncertainty, which is bad for business and research. Remaining in a reformed and more competitive EU would offer stability and predictability as a platform for even greater success. Staying in would be better for the health and wealth of the UK."

Such claims invite derision from the Brexit camp which highlights the purely negative messages put out by Remain.

Other such claims have said or implied that, inter alia, Britain's beaches would risk becoming covered in sewage, millions of jobs would be lost, families would lose thousands of pounds a year, and life would become easier for terrorists, if Britain votes to leave the European Union in the June 23 referendum.

The 93 signatories include representatives from GlaxoSmithKline, AstraZeneca and Pfizer, three giant corporates with significant lobbying power in Brussels.

Observers say that the United States, Canada, and Australia, to name but three, have access to the best medicines in the world but are not members of the European Union.

Comments
blog comments powered by Disqus